Group 1: New Drug Listings - The new National Medical Insurance Drug List will add 114 drugs, including 50 innovative drugs, increasing the total to 3,253 drugs [1] - The Commercial Health Insurance Innovative Drug List will include 19 drugs, with 5 being CAR-T therapies [1] Group 2: Local Production Strategies - Companies like Innovent Biologics are optimistic about the market entry of their drug, "Tislelizumab," which is now covered by the national insurance [2] - Fosun Pharma has adopted different production strategies for its drugs, including "raw material reserves and flexible production" for "Luwomeitini" and a dual strategy of "short-term imports and long-term localization" for "Tianapano" [3] - Marubeni Pharma has localized production for its drugs, ensuring stable supply through hospital access and dual-channel pharmacies [3] Group 3: Accessibility Enhancements - Companies are adjusting inventory, pricing, and reimbursement information for new innovative drugs in line with national negotiation policies [4] - The "dual-channel" system allows patients to access drugs through designated medical institutions and retail pharmacies, ensuring quick prescription flow [4] - National Pharmaceutical Holdings is assisting drug companies in pricing and insurance coding for newly introduced innovative drugs in Shanghai [4] Group 4: Hospital Integration and Evaluation - Hospitals are considering various factors for integrating innovative drugs, including overall insurance funding and clinical efficacy assessments [5] - Shanghai Zhongshan Hospital is adopting a principle of "as much as possible" for including new innovative drugs in their formulary [5] - Research and monitoring of adverse reactions for newly added innovative drugs are being emphasized to ensure safety and efficacy in clinical settings [5]